Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Apr;71(4):712–716. doi: 10.1038/bjc.1995.139

Induction of hepatic metallothionein I in tumour-bearing mice.

D M Kloth 1, J L Chin 1, M G Cherian 1
PMCID: PMC2033733  PMID: 7710933

Abstract

Metallothionein (MT) is an intracellular metal-binding protein which has been implicated in various biological roles, including heavy-metal detoxification and zinc and copper homeostasis, and has putative antioxidant properties. High levels of MT have been detected in certain human tumours, but its functions are unclear. The presence of tumour may cause stress conditions along with alterations in host metabolism, such as the redistribution of metals and, subsequently, in changes in hepatic MT isoforms. The distribution of basal levels of MT-1 and MT-11 isoforms in livers of different strains of mice and their induction in mice inoculated with tumour cells are investigated. While Balb-c, C57/BL and CD1 mice strains had an equal distribution of both hepatic MT isoforms, MT-I and MT-II. In addition, MT-I was the predominant isoform synthesised (> 88%) in the livers of all strains of mice at 24 h after injection with either cadmium or zinc salts. After inoculation with human testicular T7800 or T7799 tumour cells, the major form of MT induced in the livers of nude (nu/nu) mice was Zn-MT-I, and its concentration was positively correlated with the size of the inoculated tumours (r2 = 0.85). A similar positive relation was found in the livers of Balb-c mice inoculated with MM45T mouse bladder tumour cells (r2 = 0.96). Following surgical removal of T7800 tumour, hepatic MT concentrations returned to basal values. There was an increase in plasma MT levels in tumour-bearing mice and it was positively correlated with the increase in hepatic MT levels. These results demonstrate a specific increase in hepatic MT-I isoform in tumour-bearing mice, and this may be due to a generalised stress during tumour growth.

Full text

PDF
712

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. A., Howell S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990 Feb;2(2):35–43. [PubMed] [Google Scholar]
  2. Bremner I., Beattie J. H. Metallothionein and the trace minerals. Annu Rev Nutr. 1990;10:63–83. doi: 10.1146/annurev.nu.10.070190.000431. [DOI] [PubMed] [Google Scholar]
  3. Chan H. M., Cherian M. G., Bremner I. Quantification of metallothionein isoforms using an enzyme-linked immunosorbent assay (ELISA) with two specific antisera. Toxicol Appl Pharmacol. 1992 Oct;116(2):267–270. doi: 10.1016/0041-008x(92)90306-d. [DOI] [PubMed] [Google Scholar]
  4. Chan H. M., Pringle G. A., Cherian M. G. Heterogeneity of antibodies to metallothionein isomers and development of a simple enzyme-linked immunosorbent assay. J Biochem Toxicol. 1992 Winter;7(4):219–227. doi: 10.1002/jbt.2570070405. [DOI] [PubMed] [Google Scholar]
  5. Cherian M. G., Huang P. C., Klaassen C. D., Liu Y. P., Longfellow D. G., Waalkes M. P. National Cancer Institute workshop on the possible roles of metallothionein in carcinogenesis. Cancer Res. 1993 Feb 15;53(4):922–925. [PubMed] [Google Scholar]
  6. Cherian M. G. The significance of the nuclear and cytoplasmic localization of metallothionein in human liver and tumor cells. Environ Health Perspect. 1994 Sep;102 (Suppl 3):131–135. doi: 10.1289/ehp.94102s3131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chin J. L., Banerjee D., Kadhim S. A., Kontozoglou T. E., Chauvin P. J., Cherian M. G. Metallothionein in testicular germ cell tumors and drug resistance. Clinical correlation. Cancer. 1993 Nov 15;72(10):3029–3035. doi: 10.1002/1097-0142(19931115)72:10<3029::aid-cncr2820721027>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  8. Cousins R. J., Leinart A. S. Tissue-specific regulation of zinc metabolism and metallothionein genes by interleukin 1. FASEB J. 1988 Oct;2(13):2884–2890. doi: 10.1096/fasebj.2.13.2458983. [DOI] [PubMed] [Google Scholar]
  9. De S. K., McMaster M. T., Andrews G. K. Endotoxin induction of murine metallothionein gene expression. J Biol Chem. 1990 Sep 5;265(25):15267–15274. [PubMed] [Google Scholar]
  10. DeWys W., Pories W. Inhibition of a spectrum of animal tumors by dietary zinc deficiency. J Natl Cancer Inst. 1972 Feb;48(2):375–381. [PubMed] [Google Scholar]
  11. Friedman R. L., Stark G. R. alpha-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences. Nature. 1985 Apr 18;314(6012):637–639. doi: 10.1038/314637a0. [DOI] [PubMed] [Google Scholar]
  12. Hamer D. H. Metallothionein. Annu Rev Biochem. 1986;55:913–951. doi: 10.1146/annurev.bi.55.070186.004405. [DOI] [PubMed] [Google Scholar]
  13. Johnson S. W., Ozols R. F., Hamilton T. C. Mechanisms of drug resistance in ovarian cancer. Cancer. 1993 Jan 15;71(2 Suppl):644–649. doi: 10.1002/cncr.2820710224. [DOI] [PubMed] [Google Scholar]
  14. Kadhim S. A., Chin J. L. Anti-tumor effect of tumor necrosis factor and its induction of tumor variant of MBT-2 transitional cell carcinoma of the bladder. J Urol. 1988 May;139(5):1091–1094. doi: 10.1016/s0022-5347(17)42793-5. [DOI] [PubMed] [Google Scholar]
  15. Kershaw W. C., Lehman-McKeeman L. D., Klaassen C. D. Hepatic isometallothioneins in mice: induction in adults and postnatal ontogeny. Toxicol Appl Pharmacol. 1990 Jun 15;104(2):267–275. doi: 10.1016/0041-008x(90)90301-a. [DOI] [PubMed] [Google Scholar]
  16. Kontozoglou T. E., Banerjee D., Cherian M. G. Immunohistochemical localization of metallothionein in human testicular embryonal carcinoma cells. Virchows Arch A Pathol Anat Histopathol. 1989;415(6):545–549. doi: 10.1007/BF00718648. [DOI] [PubMed] [Google Scholar]
  17. Kägi J. H., Schäffer A. Biochemistry of metallothionein. Biochemistry. 1988 Nov 15;27(23):8509–8515. doi: 10.1021/bi00423a001. [DOI] [PubMed] [Google Scholar]
  18. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  19. Matsubara J., Tajima Y., Karasawa M. Metallothionein induction as a potent means of radiation protection in mice. Radiat Res. 1987 Aug;111(2):267–275. [PubMed] [Google Scholar]
  20. Meskel H. H., Cherian M. G., Martinez V. J., Veinot L. A., Frei J. V. Metallothionein as an epithelial proliferative compartment marker for DNA flow cytometry. Mod Pathol. 1993 Nov;6(6):755–760. [PubMed] [Google Scholar]
  21. Min K. S., Terano Y., Onosaka S., Tanaka K. Induction of hepatic metallothionein by nonmetallic compounds associated with acute-phase response in inflammation. Toxicol Appl Pharmacol. 1991 Oct;111(1):152–162. doi: 10.1016/0041-008x(91)90144-4. [DOI] [PubMed] [Google Scholar]
  22. Minkel D. T., Dolhun P. J., Calhoun B. L., Saryan L. A., Petering D. H. Zinc deficiency and growth of Ehrlich ascites tumor. Cancer Res. 1979 Jul;39(7 Pt 1):2451–2456. [PubMed] [Google Scholar]
  23. Naganuma A., Satoh M., Imura N. Specific reduction of toxic side effects of adriamycin by induction of metallothionein in mice. Jpn J Cancer Res. 1988 Mar;79(3):406–411. doi: 10.1111/j.1349-7006.1988.tb01605.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Palmiter R. D., Findley S. D., Whitmore T. E., Durnam D. M. MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6333–6337. doi: 10.1073/pnas.89.14.6333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Petering H. G., Buskirk H. H., Crim J. A. The effect of dietary mineral supplements of the rat on the antitumor activity of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone). Cancer Res. 1967 Jun;27(6):1115–1121. [PubMed] [Google Scholar]
  26. Phillips J. L., Sheridan P. J. Effect of zinc administration on the growth of L1210 and BW5147 tumors in mice. J Natl Cancer Inst. 1976 Aug;57(2):361–363. doi: 10.1093/jnci/57.2.361. [DOI] [PubMed] [Google Scholar]
  27. Quaife C. J., Findley S. D., Erickson J. C., Froelick G. J., Kelly E. J., Zambrowicz B. P., Palmiter R. D. Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry. 1994 Jun 14;33(23):7250–7259. doi: 10.1021/bi00189a029. [DOI] [PubMed] [Google Scholar]
  28. Richards M. P. Recent developments in trace element metabolism and function: role of metallothionein in copper and zinc metabolism. J Nutr. 1989 Jul;119(7):1062–1070. doi: 10.1093/jn/119.7.1062. [DOI] [PubMed] [Google Scholar]
  29. Satoh M., Kloth D. M., Kadhim S. A., Chin J. L., Naganuma A., Imura N., Cherian M. G. Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis. Cancer Res. 1993 Apr 15;53(8):1829–1832. [PubMed] [Google Scholar]
  30. Scheuhammer A. M., Cherian M. G. Quantification of metallothioneins by a silver-saturation method. Toxicol Appl Pharmacol. 1986 Mar 15;82(3):417–425. doi: 10.1016/0041-008x(86)90277-2. [DOI] [PubMed] [Google Scholar]
  31. Schroeder J. J., Cousins R. J. Interleukin 6 regulates metallothionein gene expression and zinc metabolism in hepatocyte monolayer cultures. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3137–3141. doi: 10.1073/pnas.87.8.3137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sobocinski P. Z., Canterbury W. J., Jr, Mapes C. A., Dinterman R. E. Involvement of hepatic metallothioneins in hypozincemia associated with bacterial infection. Am J Physiol. 1978 Apr;234(4):E399–E406. doi: 10.1152/ajpendo.1978.234.4.E399. [DOI] [PubMed] [Google Scholar]
  33. Takeda A., Sato T., Tamano H., Okada S. Elevation of hepatic levels of metallothionein and zinc in mice bearing experimental tumors. Biochem Biophys Res Commun. 1992 Dec 15;189(2):645–649. doi: 10.1016/0006-291x(92)92249-w. [DOI] [PubMed] [Google Scholar]
  34. Ujjani B., Krakower G., Bachowski G., Krezoski S., Shaw C. F., 3rd, Petering D. H. Host zinc metabolism and the Ehrlich ascites tumour. Zinc redistribution during tumour-related stress. Biochem J. 1986 Jan 1;233(1):99–105. doi: 10.1042/bj2330099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Woster A. D., Failla M. L., Taylor M. W., Weinberg E. D. Zinc suppression of initiation of sarcoma 180 growth. J Natl Cancer Inst. 1975 Apr;54(4):1001–1003. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES